产品
编 号：F414588
分子式：C28H22F3N7O
分子量：529.52
分子式：C28H22F3N7O
分子量：529.52
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
25mg
280
In-stock
50mg
440
In-stock
100mg
680
In-stock
200mg
988
In-stock
500mg
1931
In-stock
结构图
CAS No: 641571-10-0
产品详情
生物活性：
Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
体内研究：
Nilotinib (oral gavage, 40 mg/kg, daily, 4 weeks) shows equivalent or higher antitumor effects in BALB/cSLc-nu/nu mice with GIST xenograft.Nilotinib has a significant healing effect on the macroscopic and microscopic pathologic scores and ensures considerable mucosal healing in the indomethacin-induced enterocolitis rat model while decreases the PDGFR α and β levels and apoptotic scores in the colon.Animal Model:BALB/cSLc-nu/nu mice with GIST xenograft (GK1X, GK2X and GK3X)
Dosage:40 mg/kg
Administration:Oral gavage; daily; 4 weeks
Result:Inhibited tumor growth by 69.6% in GK1X, 85.3% in GK2X and 47.5% in GK3X xenograft line.
体外研究：
Nilotinib (AMN107), selective Abl inhibitor, is designed to interact with the ATP-binding site of BCR-ABL with a higher affinity than imatinib while being significantly more potent compared with imatinib (IC50Nilotinib 相关抗体:
Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
体内研究：
Nilotinib (oral gavage, 40 mg/kg, daily, 4 weeks) shows equivalent or higher antitumor effects in BALB/cSLc-nu/nu mice with GIST xenograft.Nilotinib has a significant healing effect on the macroscopic and microscopic pathologic scores and ensures considerable mucosal healing in the indomethacin-induced enterocolitis rat model while decreases the PDGFR α and β levels and apoptotic scores in the colon.Animal Model:BALB/cSLc-nu/nu mice with GIST xenograft (GK1X, GK2X and GK3X)
Dosage:40 mg/kg
Administration:Oral gavage; daily; 4 weeks
Result:Inhibited tumor growth by 69.6% in GK1X, 85.3% in GK2X and 47.5% in GK3X xenograft line.
体外研究：
Nilotinib (AMN107), selective Abl inhibitor, is designed to interact with the ATP-binding site of BCR-ABL with a higher affinity than imatinib while being significantly more potent compared with imatinib (IC50Nilotinib 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备